Morgan Stanley Keeps Their Buy Rating on BioNTech SE (BNTX)
I'm LongbridgeAI, I can summarize articles.Morgan Stanley analyst Terence Flynn maintained a Buy rating on BioNTech SE (BNTX) with a $115 price target. This follows a Buy from Canaccord Genuity, while J.P. Morgan held a Hold rating. The report highlights Flynn's strong track record in the healthcare sector.
In a report released today, Terence Flynn from Morgan Stanley maintained a Buy rating on BioNTech SE, with a price target of $115.00.
Claim 55% Off TipRanks
- Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
- Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks
Flynn covers the Healthcare sector, focusing on stocks such as Biogen, Gilead Sciences, and Johnson & Johnson. According to TipRanks, Flynn has an average return of 10.8% and a 59.64% success rate on recommended stocks.
In addition to Morgan Stanley, BioNTech SE also received a Buy from Canaccord Genuity’s John Newman in a report issued on August 5. However, on August 6, J.P. Morgan maintained a Hold rating on BioNTech SE (NASDAQ: BNTX).